Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Mar 20, 2024 | -$0.08 | -$0.46 | Miss |
| Nov 9, 2023 | -$0.24 | -$0.10 | Beat |
| Aug 21, 2023 | -$0.30 | -$0.12 | Beat |
| May 11, 2023 | -$0.33 | -$0.66 | Miss |
| Mar 15, 2023 | -$0.33 | -$0.46 | Miss |
| Nov 10, 2022 | -$0.64 | -$0.51 | Beat |